Aggregated price index with volume information
Summary:
- Generic Drug Makers stocks up 1.6% on average while median return up 1.3% in a day
- Generic Drug Makers stocks down 0.8% on average while median return down 0.6% in a week
- Generic Drug Makers stocks down 5.8% on average while median return down 6.9% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $ACRS 5.0%
- 1M losers are : Losers for past month are $BHC -9.4%, $COLL -10.2%, $AMRX -10.9%, $CHRS -16.9%, $EGRX -18.5%
- 1W winners are : Winners for past week are $ACRS 3.3%, $PRGO 1.6%, $AMPH 0.9%, $EGRX 0.9%, $TARO 0.6%
- 1W losers are : Losers for past week are $AMRX -1.8%, $ANIP -2.1%, $COLL -2.4%, $TEVA -3.3%, $CHRS -7.6%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 22.4%, for the past 3 months is 11.2%
In the past month for a 5 days rolling window, the highest corrrelation is 44.2%, the lowest correlation is -3.0%, the latest correlation is 37.5%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 68.7% between COLL and TEVA
The lowest correlation is -29.7% between LCI and RDY
BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateFriday, May 10, 2024 Time8:30 a.m. ET T
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
REYKJAVIK, Iceland & PARSIPPANY, N.J., April 16, 2024--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
BRIDGEWATER, N.J., April 16, 2024--Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
TEL AVIV, Israel & PARSIPPANY, N.J., April 16, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body